BridgeBio Pharma Inc (FRA:2CL)
€ 60.3 +0.020 (+0.03%) Market Cap: 12.02 Bil Enterprise Value: 13.40 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

BridgeBio Pharma Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2026 / 04:30PM GMT
Release Date Price: €62.36 (+7.78%)
Eliana Merle
Barclays Capital Inc. - Analyst

Hi, everyone. Good afternoon. I'm Eli Merle, one of the biotech analysts here at Barclays. Very excited to have Neil Kumar here with us joining from BridgeBio. CEO. Thank you so much, Neil, for making the time.

Neil Kumar
BridgeBio Pharma Inc - Chief Executive Officer, Director

Thanks for having me. Really appreciate it.

Questions & Answers

Eliana Merle
Barclays Capital Inc. - Analyst

A lot to talk about across your four late-stage programs. Maybe just because it's topical now. Let's talk about what we learned yesterday from the team IP case.

Neil Kumar
BridgeBio Pharma Inc - Chief Executive Officer, Director

Sure. Yes, get right into it. So just as a reminder, this is an IP situation that is related to a competitor's drug products, Allstate relatively high level in and around it. But effectively, there are two key battlegrounds that I think people are paying attention to in the context of this trial and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot